1. Phase II clinical trial using anti-CD3 × anti-HER2 bispecific antibody armed activated T cells (HER2 BATs) consolidation therapy for HER2 negative (0–2+) metastatic breast cancer. Issue 6 (11th June 2021) Authors: Lum, Lawrence G.; Al-Kadhimi, Zaid; Deol, Abhinav; Kondadasula, Vidya; Schalk, Dana; Tomashewski, Elyse; Steele, Patricia; Fields, Kristie; Giroux, Melissa; Liu, Qin; Flaherty, Lawrence; Simon, Michael; Thakur, Archana Journal: Journal for immunotherapy of cancer Issue: Volume 9:Issue 6(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗